Management Strategies for Noncardiac Surgery Following a Coronary Artery Event
Thomas F Whayne1, Sibu P Saha2
1Gill Heart and Vascular Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536-0200, USA. twhayn0@uky.edu.
Insights
Making noncardiac surgery safer after a coronary artery event involves optimizing medications. Continuing statins and angiotensin-converting enzyme inhibitors or blockers is recommended, especially for diabetics, to reduce cardiovascular risk.
Area of Science:
- Cardiology
- Perioperative Medicine
- Vascular Surgery
Background:
- Noncardiac surgery poses increased risk following coronary artery events like ACS, PCI, and CABG.
- High functional capacity (≥4.0 METs) is associated with improved cardiovascular outcomes.
- Peripheral arterial disease (PAD), indicated by low ABI, is linked to increased cardiovascular risk.
Purpose of the Study:
- To review strategies for improving the safety of noncardiac surgery in patients with a history of coronary artery events.
- To identify key factors and interventions that mitigate perioperative cardiovascular risk.
Main Methods:
- Review of recent findings on perioperative cardiovascular risk management.
- Analysis of the impact of medications (beta-blockers, statins, ACEI/ARBs) on surgical outcomes.
- Evaluation of diagnostic tools (stress tests, ABI) and timing of surgery.
Main Results:
- Perioperative beta-blockade shows limited benefit, with de novo use reserved for high-risk vascular surgery patients.
- Statins demonstrate good evidence for cardiovascular risk reduction, particularly in diabetic patients.
- ACEI or ARB use in diabetics is associated with decreased 30-day perioperative mortality.
Conclusions:
- Optimal timing for elective noncardiac surgery post-coronary event is 180 days.
- Continuing statins and ACEI/ARBs can significantly decrease perioperative cardiovascular risk.
- Risk stratification using functional capacity and ABI is crucial for patient management.
Purpose Of Review:
Coronary artery event includes acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) surgery. Following such an event, risk of noncardiac surgery is increased. Of major concern is what can make this surgery safer?
Recent Findings:
High functional capacity improves cardiovascular (CV) risk; at least 4.0 metabolic equivalents (METs) on stress test are favorable. Risk scores can suggest need for further evaluation. Coronary angiography prior to surgery usually is not indicated since revascularization shows disappointing CV risk reduction results. Due to high association of peripheral arterial disease (PAD) with coronary artery disease (CAD), low ankle-brachial index (ABI) indicates increased CV risk. New perioperative beta blockade has shown disappointing benefit, but if ongoing should be continued. De novo perioperative beta blockade is for the highest CV risk patient undergoing noncardiac vascular surgery. Good evidence supports CV risk reduction from new or existing statin in the perioperative period, especially for the diabetic. Diabetics should also be on an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) secondarily, during the perioperative period to decrease 30-day perioperative mortality. Optimal timing of elective noncardiac surgery following a coronary artery event appears to be 180 days with CV risk decreased by a statin and an ACEI or an ARB.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:26Acute Coronary Syndrome V: Nursing Management
01:27Coronary Artery Disease V: Interprofessional Care
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures